Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 13 de 13
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Opt Express ; 32(1): 396-407, 2024 Jan 01.
Artículo en Inglés | MEDLINE | ID: mdl-38175070

RESUMEN

What we believe to be a new type of transparent photon sieve is presented with application for presbyopia correction. Inspired by blazed gratings, we propose to design an intracorneal implant with slanted holes. The slopes introduce a new degree of freedom, breaking the symmetry of energy distribution along the optical axis and allowing to balance the energy between near and far vision. This new implant design is presented together with the simulation, manufacturing and validation methods. The first experimental results obtained with an implant manufactured in a biocompatible material are presented confirming the potential of the approach.

2.
Praxis (Bern 1994) ; 99(13): 767-77; quiz 776, 2010 Jun 23.
Artículo en Alemán | MEDLINE | ID: mdl-20571998

RESUMEN

We report on a patient with Pneumocystis jirovecii pneumonia who developed fever, rash, eosinophilia and hepatitis 10 days after initiation of a therapy with sulfamethoxazole and trimethoprim. A DRESS syndrome was diagnosed and the therapy was changed successfully to pyrimethamine and dapsone. We describe the clinical picture, causative drugs, pathogenesis, differential diagnoses and therapy of this life-threatening disease to acquaint the general practitioner with it.


Asunto(s)
Erupciones por Medicamentos/diagnóstico , Hipersensibilidad a las Drogas/diagnóstico , Eosinofilia/etiología , Exantema/etiología , Fiebre de Origen Desconocido/etiología , Pruebas de Función Hepática , Infecciones Oportunistas/tratamiento farmacológico , Pneumocystis carinii , Neumonía por Pneumocystis/tratamiento farmacológico , Combinación Trimetoprim y Sulfametoxazol/efectos adversos , Combinación Trimetoprim y Sulfametoxazol/uso terapéutico , Anticuerpos Monoclonales/administración & dosificación , Anticuerpos Monoclonales/efectos adversos , Anticuerpos Monoclonales de Origen Murino , Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Ciclofosfamida/administración & dosificación , Ciclofosfamida/efectos adversos , Diagnóstico Diferencial , Doxorrubicina/administración & dosificación , Doxorrubicina/efectos adversos , Humanos , Linfoma de Células T/tratamiento farmacológico , Masculino , Persona de Mediana Edad , Infecciones Oportunistas/inducido químicamente , Neumonía por Pneumocystis/inducido químicamente , Prednisona/administración & dosificación , Prednisona/efectos adversos , Rituximab , Vincristina/administración & dosificación , Vincristina/efectos adversos
3.
Praxis (Bern 1994) ; 99(6): 377-9, 2010 Mar 17.
Artículo en Alemán | MEDLINE | ID: mdl-20235030

RESUMEN

In a patient with a bacterial nephritis and renal stones an incidental finding of a complicated renal cyst on the opposite side was made on CT scan. In contrast to the CT findings, on ultrasound examination the lesion appeared to be a solid mass. The injection of ultrasound contrast material confirmed this by showing an enhancement of the whole lesion. Finally, the histological finding after nephrectomy results in a renal cell carcinoma pT1a. In this situation contrast enhanced ultrasound seems to be more sensitive than CT scan in detecting the perfusion of a renal mass.


Asunto(s)
Carcinoma de Células Renales/diagnóstico , Aumento de la Imagen , Hallazgos Incidentales , Enfermedades Renales Quísticas/diagnóstico , Neoplasias Renales/diagnóstico , Tomografía Computarizada por Rayos X , Ultrasonografía , Anciano , Carcinoma de Células Renales/patología , Humanos , Enfermedades Renales Quísticas/patología , Neoplasias Renales/patología , Masculino , Estadificación de Neoplasias
4.
Ultraschall Med ; 31(2): 175-81, 2010 Apr.
Artículo en Alemán | MEDLINE | ID: mdl-20183778

RESUMEN

AIM: Described are the clinical and, especially, the contrast-enhanced ultrasonographic presentation and recovery of four cases of fascioliasis occurring between December 2008 and February 2009. MATERIALS AND METHODS: A detailed history, clinical examination and laboratory investigation were followed by contrast-enhanced ultrasonography of the liver and serological evidence for the presence of antibodies. A final contrast-enhanced ultrasound was performed 6 weeks after treatment with triclabendazole. RESULTS: The patients displayed a variety of symptoms ranging from vasospastic myocardial infarction diagnosed via coronary angiography and a first-time occurrence of migraine as a result of hypereosinophilia to fever with weight loss and tumor-like liver lesions. The contrast-enhanced ultrasonographic hepatic changes in fascioliasis are characterized by segmental arterial hyperemia with emphasis on the liver periphery and subcapsular canalicular sparing corresponding to parenchymal necrosis and hemorrhage. In the later phases areas with inflammatory changes were unmasked due to phlebitis of the small portal vessels and granulomatous parenchymal changes. All four patients were successfully treated with triclabendazole without experiencing any serious side effects. CONCLUSION: Contrast-enhanced ultrasonography is well suited for the diagnosis and monitoring of hepatic fascioliasis.


Asunto(s)
Fascioliasis/diagnóstico por imagen , Adulto , Antihelmínticos/uso terapéutico , Bencimidazoles/uso terapéutico , Biopsia , Medios de Contraste/administración & dosificación , Diagnóstico Diferencial , Fascioliasis/tratamiento farmacológico , Fascioliasis/patología , Femenino , Estudios de Seguimiento , Humanos , Hígado/diagnóstico por imagen , Hígado/patología , Masculino , Persona de Mediana Edad , Fosfolípidos , Sensibilidad y Especificidad , Hexafluoruro de Azufre , Tomografía Computarizada por Rayos X , Triclabendazol , Ultrasonografía
5.
Internist (Berl) ; 51(4): 528-32, 2010 Apr.
Artículo en Alemán | MEDLINE | ID: mdl-20169329

RESUMEN

We report a case of severe intoxication with extended-release verapamil. In addition to cardiovascular toxicities with hypotension, atrioventricular block and bradycardia, the patient suffered from grand-mal seizure and pulmonary edema 13 and 48 hours respectively, after ingestion of 4.8 g of extended-release verapamil. Adverse reactions after intoxications with extended-release tablets appear delayed with prolonged manifestation of symptoms. Early and repetitive administration of activated charcoal and antegrade whole bowel lavage are crucial, even in primary asymptomatic patients.


Asunto(s)
Edema Pulmonar/inducido químicamente , Edema Pulmonar/diagnóstico , Convulsiones/inducido químicamente , Convulsiones/diagnóstico , Verapamilo/toxicidad , Adulto , Enfermedades Cardiovasculares/complicaciones , Diagnóstico Diferencial , Femenino , Humanos
6.
Praxis (Bern 1994) ; 97(5): 235-9; quiz 240-1, 2008 Mar 05.
Artículo en Alemán | MEDLINE | ID: mdl-18548805

RESUMEN

A 55-year-old male patient was hospitalized with severe nausea, vomiting and icterus. Laboratory testing showed hepatocellular damage. After exhaustive testing, the exclusion diagnosis of a toxic hepatitis was reached. There was a strong temporal correlation with the ingestion of Hong Hua 29, a preparation from Traditional Chinese Medicine (TCM). This medication had been started twelve days prior to the first appearance of symptoms. The existing drug regimen included gabapentin (Neurontin), esomeprazole (Nexium) and prednisone (Prednison Streuli) for the therapy of an acute sensory and motor neuropathy of unknown aetiology. After cessation of Hong Hua 29, gabapentin and esomeprazole, transaminase levels started to declined and normalized within three months. According to the Swissmedic criteria of imputability, a causal correlation between the observed symptoms and the administration of Hong Hua 29 is possible.


Asunto(s)
Enfermedad Hepática Inducida por Sustancias y Drogas/etiología , Medicamentos Herbarios Chinos/toxicidad , Laca/toxicidad , Neuritis/inducido químicamente , Neuritis/tratamiento farmacológico , Enfermedades Profesionales/inducido químicamente , Biopsia , Enfermedad Hepática Inducida por Sustancias y Drogas/patología , Colestasis Intrahepática/inducido químicamente , Colestasis Intrahepática/diagnóstico , Colestasis Intrahepática/patología , Quimioterapia Combinada , Medicamentos Herbarios Chinos/uso terapéutico , Humanos , Hígado/patología , Pruebas de Función Hepática , Masculino , Persona de Mediana Edad , Neuritis/diagnóstico , Neuritis/patología , Enfermedades Profesionales/diagnóstico , Enfermedades Profesionales/patología
8.
Praxis (Bern 1994) ; 96(17): 673-6; quiz 677-8, 2007 Apr 25.
Artículo en Alemán | MEDLINE | ID: mdl-17491196

RESUMEN

In an 81-year-old patient with a history of long-standing stable chronic renal failure a diagnosis of multiple myeloma was made. After an initial chemotherapy, a therapy with intravenous pamidronate, 90 mg monthly, was initiated. After four years of well tolerated therapy, pamidronate was stopped and zoledronate, 4 mg intravenously every four weeks, was started. After approximately one year, an elevated plasma creatinine was noted for the'first time, progressing to end stage renal failure within the next months. At admission, besides end-stage renal failure, severe asymptomatic hypocalcemia was noted. Renal biopsy findings included severe tubulointerstitial damage compatible with drug-induced tubular injury. Prerenal and postrenal failure could be excluded as well as myeloma kidney. The diagnosis of zoledronate-associated end-stage renal failure was made and treatment with hemodialysis was started. Hypocalcemia was treated with calcium and vitamin D3 supplements. After two years of follow up, the patient still required hemodialysis.


Asunto(s)
Sistemas de Registro de Reacción Adversa a Medicamentos , Conservadores de la Densidad Ósea/efectos adversos , Difosfonatos/efectos adversos , Hipocalcemia/inducido químicamente , Imidazoles/efectos adversos , Fallo Renal Crónico/inducido químicamente , Lesión Renal Aguda/inducido químicamente , Factores de Edad , Anciano , Anciano de 80 o más Años , Biopsia , Conservadores de la Densidad Ósea/administración & dosificación , Calcio/uso terapéutico , Creatinina/sangre , Difosfonatos/administración & dosificación , Difosfonatos/uso terapéutico , Progresión de la Enfermedad , Femenino , Estudios de Seguimiento , Humanos , Imidazoles/administración & dosificación , Fallo Renal Crónico/sangre , Fallo Renal Crónico/complicaciones , Fallo Renal Crónico/diagnóstico , Fallo Renal Crónico/patología , Fallo Renal Crónico/terapia , Túbulos Renales/efectos de los fármacos , Túbulos Renales/patología , Persona de Mediana Edad , Mieloma Múltiple/complicaciones , Pamidronato , Diálisis Renal , Factores de Riesgo , Suiza , Factores de Tiempo , Vitamina D/uso terapéutico , Ácido Zoledrónico
9.
Eur J Vasc Endovasc Surg ; 33(5): 605-9, 2007 May.
Artículo en Inglés | MEDLINE | ID: mdl-17227717

RESUMEN

OBJECTIVES: To evaluate the influence of secondary infection on major amputation in chronic critical leg ischemia (CLI). DESIGN: Prospective, controlled observational study. MATERIALS AND METHODS: Sixty-seven patients with CLI and ischemic lesions participated in the study. Presence of infection was defined by clinical, laboratory and radiological criteria. Patients were categorized as having no local infection, soft tissue infection or osteomyelitis treated without antibiotics, amoxicillin/clavulanacid for 1 month or ciprofloxacin and clindamycin for 3 months, respectively. Clinical outcome was assessed at 2, 6 and 12 months. Study endpoints were major amputation and mortality. Analyses were performed using the Kaplan-Meier method. RESULTS: Forty-seven of 67 patients had a local infection. Major amputation was lower in patients with successful revascularization as compared to patients unsuitable for or with failed (without) revascularization (0% vs 26%, p<0.01). In patients with successful revascularization the probability of complete healing was lower with secondary infection (23% vs 71%, p=0.03). In patients without revascularization complete healing was rare (<10%), but secondary infection did not influenced major amputation, mortality or serious adverse events. CONCLUSION: Secondary infection reduces the likelihood of successful healing following revascularisation of CLI.


Asunto(s)
Amputación Quirúrgica , Infecciones/complicaciones , Isquemia/complicaciones , Isquemia/cirugía , Pierna/irrigación sanguínea , Anciano , Antibacterianos/uso terapéutico , Enfermedades Cardiovasculares/epidemiología , Enfermedad Crónica , Femenino , Humanos , Infecciones/tratamiento farmacológico , Imagen por Resonancia Magnética , Masculino , Estudios Prospectivos , Factores de Riesgo , Cicatrización de Heridas
11.
Br J Cancer ; 95(7): 848-52, 2006 Oct 09.
Artículo en Inglés | MEDLINE | ID: mdl-16969352

RESUMEN

This phase II study was conducted to determine the efficacy and toxicity of a gemcitabine (GEM) and oxaliplatin (OX) chemotherapy protocol in patients with unresectable biliary tract cancer (BTC). Patients were treated with GEM 1000 mg m-2 (30 min infusion) on days 1, 8, 15, and OX 100 mg m-2 (2 h infusion) on days 1 and 15 (gemcitabine and oxaliplatin (GEMOX-3 protocol), repeated every 28 days. The data were collected according to the Simon 2-stage design for a single centre phase II study (alpha=0.05; beta=0.2). Primary end point was response rate; secondary end points were time-to-progression (TTP), median survival, and safety profile. Thirty-one patients were enrolled in the study between July 2002 and April 2005. Therapeutic responses were as follows: partial response in eight patients (26%, 95% confidence interval (CI) 14-44), stable disease in 14 patients (45%, 95%CI 29-62), resulting in a disease control rate of 71%. Nine patients (29%, 95%CI 16-47) had progressive disease. Median TTP was 6.5 months. Median overall survival was 11 months. Common Toxicity Criteria (CTC) Grade 3-4 toxicities were transient thrombocytopenia (23%), peripheral sensory neuropathy (19%), leucopenia (16%), and anaemia (10%). In conclusion the GEMOX-3 protocol is active and well tolerated in patients with advanced BTC. It can be applied in an outpatient setting with three visits per month only.


Asunto(s)
Adenocarcinoma/tratamiento farmacológico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Neoplasias del Sistema Biliar/tratamiento farmacológico , Desoxicitidina/análogos & derivados , Compuestos Organoplatinos/administración & dosificación , Adulto , Anciano , Desoxicitidina/administración & dosificación , Desoxicitidina/efectos adversos , Femenino , Terapia de Infusión a Domicilio , Humanos , Masculino , Persona de Mediana Edad , Compuestos Organoplatinos/efectos adversos , Oxaliplatino , Análisis de Supervivencia , Resultado del Tratamiento , Gemcitabina
13.
Vasa ; 32(1): 18-21, 2003 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-12677760

RESUMEN

BACKGROUND: Aim was to analyze the association between local infection and amputation rate in patients with chronic critical limb ischemia (CLI) with or without successful revascularization. PATIENTS AND METHODS: We performed a retrospective analysis of 56 consecutive patients with 57 critically ischemic legs seen at the University Hospital Bern. Patients with CLI were selected if ischemic lesions and follow-up of more than 2 months were documented. Infection was suggested when 2 of the following criterion were present: temperature > 37 degrees C, C-reactive protein > 50 mg/L, leukocytes > 10 x 10(3)/microliter ("2 of 3" criterion), or a putrid secretion was documented ("secretion" criterion). RESULTS: In patients with successful revascularization (n = 39), there was a significant shift from 10.3% major to 33.3% minor amputations (Chi Square p value = 0.014) as compared to patients without or with failed revascularization (n = 18) with 44.4% and 11.1% (Chi Square p value = 0.008), respectively. An infection was suggested in 22 of 53 limbs (41.5%) according to the "2 of 3" criterion, and 30 of 57 limbs (52.6%) satisfying the "secretion" criterion. Both criteria, were significantly more common in patients undergoing amputation as compared to patients without amputation (p = 0.001). Multiple lesions were more common in patients with major amputations (p = 0.026). CONCLUSION: Successful revascularization effectively reduces major amputations and leads to healing of ischemic ulcers. Secondary foot infections are frequent. Infections are associated with a significantly higher rate of minor and major amputations, also in patients with successful revascularization, and should be treated adequately as well as in time with antibiotics.


Asunto(s)
Amputación Quirúrgica/estadística & datos numéricos , Infecciones Bacterianas/cirugía , Isquemia/cirugía , Úlcera de la Pierna/cirugía , Pierna/irrigación sanguínea , Adulto , Anciano , Anciano de 80 o más Años , Angioplastia de Balón/estadística & datos numéricos , Infecciones Bacterianas/complicaciones , Infecciones Bacterianas/epidemiología , Distribución de Chi-Cuadrado , Interpretación Estadística de Datos , Femenino , Estudios de Seguimiento , Humanos , Isquemia/complicaciones , Isquemia/epidemiología , Pierna/cirugía , Úlcera de la Pierna/complicaciones , Úlcera de la Pierna/epidemiología , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Factores de Riesgo , Suiza , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA